Last reviewed · How we verify
NCT03245970
Impedance Cardiography to Decrease the Risk of Preeclampsia
EARLY_PHASE1 trial testing Labetalol Hydrocholoride 200 mg orally every 12 hours in Chronic Hypertension Complicating Pregnancy (Diagnosis). Withdrawn.
29 February 2020
Quick facts
| Lead sponsor | University of Tennessee Medical Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Start date | 24 April 2017 |
| Primary completion | 29 February 2020 |
| Estimated completion | 29 February 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Labetalol Hydrocholoride 200 mg orally every 12 hours — full drug profile →
- Nifedipine 60 mg orally daily — full drug profile →
- Atenolol 25 mg daily — full drug profile →
Conditions studied
- Chronic Hypertension Complicating Pregnancy (Diagnosis) — all drugs for Chronic Hypertension Complicating Pregnancy (Diagnosis) →
- Preeclampsia — all drugs for Preeclampsia →
Sponsor
University of Tennessee Medical Center
Who can join
Adults 18 to 51, female only, with Chronic Hypertension Complicating Pregnancy (Diagnosis) or Preeclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if the use of impedance cardiography can identify appropriate medications for use in treating chronic hypertensive patients to decrease the risk of preeclampsia.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.
Abalos E, Duley L, Steyn DW, Gialdini C. · · 2018 · cited 115× · PMID 30277556 · DOI 10.1002/14651858.cd002252.pub4 -
Toward personalized management of chronic hypertension in pregnancy.
Magee LA, Khalil A, Kametas N, von Dadelszen P. · · 2022 · cited 14× · PMID 32687817 · DOI 10.1016/j.ajog.2020.07.026
Verify or expand the search:
- PubMed search for NCT03245970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Tennessee Medical Center trials
Trials by the same sponsor.
- NCT05206305 — Sensory-Evoked Cortical Gamma Oscillation · NA · recruiting
- NCT05024344 — ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy · NA · recruiting
- NCT03710187 — HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients · Phase 2 · completed
- NCT03670160 — Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03245970 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tennessee Medical Center
- Last refreshed: 5 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03245970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing